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The main ris k factor for disease and premature death 
worldwide is high blood pressure.1 The associations 
between blood pressure and fatal coronary artery 
disease and fatal stroke have been well demonstrated.2 
However, little evidence exists from contemporary 
clinical practice on the associations between blood 
pressure and morbidity and mortality from speciﬁ c 
cardiovascular disease conditions in diﬀ erent age 
groups. Also missing are results concerning lifetime 
risk for speciﬁ c cardiovascular complications 
associated with hypertension. Eleni Rapsomaniki 
and colleagues3 now report results in The Lancet that 
extend our knowledge and understanding of blood 
pressure as a risk factor for cardiovascular disease. 
This contemporary study in a primary-care setting 
assessed electronic health records for more than a 
million patients aged 30 years or older who did not 
have cardiovascular disease, and recorded initial 
cardiovascular morbidity during a median of 5·2 years 
of follow-up.
The investigators report that the lifetime burden of 
hypertension is substantial. In a 30-year-old patient 
with hypertension, the lifetime risk for a cardiovascular 
event was 63·3% (95% CI 62·9–63·8), compared with 
46·1% (45·5–46·8) in a normotensive individual, with 
an estimated loss of 5 years free of cardiovascular 
disease. Whereas patients with moderate or severe 
hypertension should always be oﬀ ered antihypertensive 
treatment, the beneﬁ t of treatment in patients with 
mild hypertension has been subject to discussion.4 
However, the results by Rapsomaniki and colleagues3 
provide circumstantial support for starting treatment of 
mild hypertension in younger people.
In each age group, the risk for future cardiovascular 
disease was lowest in people with a systolic blood 
pressure of 90–114 mm Hg and a diastolic blood 
pressure of 60–74 mm Hg, and no increase in risk with 
low values (J-shaped curve) was noted. A novel ﬁ nding 
was that the risk associated with an increase in blood 
pressure diﬀ ered with age and speciﬁ c cardiovascular 
disease conditions. For example, the associations 
between morbidity and an increase in systolic blood 
pressure were strongest for stable angina pectoris 
(hazard ratio for a 20 mm Hg rise in systolic blood 
pressure 1·41, 95% CI 1·36–1·46), and intracerebral and 
subarachnoidal haemorrhage (1·44 [1·32–1·58] and 
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metabolic syndrome, and diabetes.3 Combining 
nebivolol and valsartan within a ﬁ xed combination 
is therefore an attractive therapeutic option in view 
of its antihypertensive eﬃ  cacy, good tolerability, and 
potential value for prevention of cardiovascular and renal 
complications in patients with hypertension. However, 
this potential remains to be tested in clinical trials with 
hard clinical endpoints.
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1·43 [1·25–1·63], respectively), whereas the risk of an 
abdominal aortic aneurysm was more closely related 
to increased diastolic blood pressure (hazard ratio 
for a 10 mm Hg rise in diastolic blood pressure 1·45, 
1·34–1·56). Furthermore, for patients aged 30 years, 
coronary artery disease accounted for most of the 
estimated loss of years free of cardiovascular disease 
associated with hypertension, whereas heart failure 
contributed to a substantial part in patients aged 
80 years. Most patients with heart failure are old, have 
an impaired quality of life and poor prognosis, and 
health-care costs are high.5 The ﬁ ndings by Rapsomaniki 
and colleagues3 indirectly support antihypertensive 
treatment also in patients 80 years or older.6
Although the eﬃ  cacy of antihypertensive drug 
therapy is undisputed, observational studies suggest 
that few patients reach target blood pressure.7 
Several steps therefore need to be taken to improve 
antihypertensive treatment and control (panel). First, 
assessment of global cardiovascular risk is essential to 
oﬀ er the best management to the individual patient. 
The study by Rapsomaniki and colleagues3 provides 
important new information to improve risk assessment, 
patient counselling, and decision making for patients 
with hypertension. Second, improvements are needed 
in caregiver support and education. Caregivers might 
think that side-eﬀ ects with treatment are a problem, 
or that available evidence to treat is insuﬃ  cient. Drugs 
might be prescribed with an inappropriate dosing, or 
inadequate drug combinations could be used. Caregiver 
organisation and systematic follow-up might also 
need improvement. 
Third, factors that can improve drug compliance and 
treatment persistence to prescribed therapy ought 
to be better understood than they are at present. 
We reported that 35% of patients newly initiated on 
antihypertensive drug therapy discontinued treatment 
within 2 years.8 Furthermore, many patients referred 
for apparently treatment-resistant hypertension do not 
seem to take their prescribed medication.9,10 Fourth, 
an increased use of home blood-pressure monitoring 
and 24 h ambulatory blood-pressure monitoring is 
important. Such use would identify patients susceptible 
to the white-coat eﬀ ect, improve risk stratiﬁ cation, 
and increase patient engagement.11 Fifth, people with 
secondary forms of hypertension can often be oﬀ ered 
speciﬁ c treatment and are thus important to identify, 
in particular those with apparently treatment-resistant 
disease. Finally, an appreciation is needed that most 
patients with remaining uncontrolled hypertension 
can be well controlled when referred to a specialist 
hypertension centre.10,12
Blood-pressure control could be improved in patients 
with hypertension. The clinical beneﬁ t of improved 
risk assessment and appropriate treatment might be 
substantial.
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Panel: Key issues to improve antihypertensive treatment 
and control 
• Assessment of global cardiovascular risk in individual 
patients
• Improve caregiver organisation, support, and education
• Increase drug compliance and treatment persistence to 
prescribed treatment 
• Expand the use of home blood-pressure monitoring and 
24 h ambulatory blood-pressure monitoring 
• Consider secondary forms of hypertension in diﬃ  cult-to-
treat patients
• Consider referral of patients with remaining uncontrolled 
hypertension to a specialist hypertension centre 
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The drugs do work: blood pressure improvement in England 
Raised blood pressure is the leading risk factor for global 
disease burden; consequently, recognition and treatment 
is a key activity in primary care. Similarly, many public 
health initiatives aim to reduce the population burden 
through reduction of salt consumption, alcohol 
consumption, and obesity with policies intended to 
increase exercise and healthy diets.1
In The Lancet, Emanuela Falaschetti and colleagues2 
report unique data from the Health Survey for England 
based on a sample of 4540 people for 2011, showing 
how detection and control of raised blood pressure has 
changed in successive samples over a 17-year period 
from 1994. Mean systolic blood pressure has fallen 
by about 5 mm Hg systolic in men and 9 mm Hg in 
women, although the prevalence of hypertension has 
remained constant. Greater than 50% more people 
were receiving treatment for hypertension in 2011 than 
in 1994, and the proportion of those on treatment 
whose blood pressure was controlled to 140/90 mm Hg 
nearly doubled; as a result, people on treatment in 2011 
had a 13 mm Hg (in men) to 16 mm Hg (in women) 
lower blood pressure than did people in 1994, which is 
associated with more intensive therapy. These secular 
changes were not adjusted for changes in age in the 
population, but the age structure of the population in 
England has remained fairly stable over this period.3 
The cross-sectional nature of Falaschetti and colleagues’ 
data make secular changes diﬃ  cult to interpret; the 
reduction in mean blood pressure in people with treated 
hypertension might partly result from lower thresholds 
for initiation of blood pressure treatment, for example in 
people with existing cardiovascular disease or diabetes, 
who make up between 15% and 20% of the study 
population.1,2 Similarly, it is diﬃ  cult to infer what the fall 
in blood pressure in untreated people was in this study 
period, because people with high blood pressures in 2011 
were more likely to be treated than in 1994. Nevertheless, 
overall the data convey a positive message, and the 
reported reductions in blood pressure will have made a 
major contribution to the fall in cardiovascular mortality 
reported in this period.4,5 The study beneﬁ ts from 
consistent and carefully protocolised methods over time, 
although the monitor used to measure blood pressure 
did change in 2003, which has been taken into account.2 
It is likely that the estimates of hypertension prevalence 
are exaggerated because of measurement of blood 
pressure on one occasion as opposed to the multiple and 
out-of-oﬃ  ce methods recommended in national and 
international guidelines.1,6 However, nurse measurement 
of blood pressure, as in Falaschetti and colleagues’ study, 
is systematically lower than that measured by a doctor, 
which will tend to mitigate against this factor.7
In terms of non-pharmacological eﬀ ects, the authors 
mention the potential eﬀ ects of salt reduction in the 
national diet, and other measures from the same survey 
allow consideration of lifestyle; changes in weight 
(5 kg increase) and alcohol consumption (a third of the 
population now drink more than 3–4 units on the heaviest 
drinking day in the past week) would be expected to 
increase blood pressure, but improved physical activity 
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